ALDX

Business Context and Reporting Period

Company: Aldeyra Therapeutics, Inc. (ALDX)
Filing Type: Form 8-K (Current Report)
Date of Report: November 1, 2023
Event Date: October 31, 2023
Context: Aldeyra entered into an exclusive option agreement with AbbVie Inc. regarding its lead asset, reproxalap, a treatment for dry eye disease.

Key Financial Metrics and Transaction Terms

This filing details a potential collaboration rather than historical financial performance. Key financial terms of the agreement include:

• Option Payment: $1 million non-refundable payment from AbbVie to Aldeyra (due within 30 days of the Effective Date).
• Option Extension Fee: $5 million non-refundable payment if the FDA decision date does not occur before December 15, 2023, and AbbVie extends the option period.
• Upfront Payment (Upon Exercise): $100 million cash payment upon execution of the Collaboration Agreement, net of the Option Payment and any Option Extension Fee.
• Milestone Payments: Up to approximately $300 million in regulatory and commercial milestones, including a $100 million milestone tied to FDA approval.
• Profit Sharing (U.S.): 60% to AbbVie, 40% to Aldeyra.
• Royalties (Non-U.S.): Tiered royalties on net sales.

Note: The filing does not provide current revenue, profit, cash flow, or debt figures for Aldeyra.

Material Changes and Agreement Structure

The primary material change is the entry into the Option Agreement, granting AbbVie rights to:

• Co-exclusive license for reproxalap in the United States.
• Exclusive license for reproxalap outside the United States.
• Right of first negotiation for other ophthalmology compounds.
• Right to review data for other ophthalmology and immunology compounds.

Exercise Period: AbbVie may exercise the option until the earliest of:

1. 10 business days after FDA approval (if approved before December 15, 2023).
2. 18 months after the Effective Date (if the Option Extension Fee is paid and FDA approval is delayed).
3. December 23, 2023 (if no extension fee is paid and FDA approval is delayed).

Outlook, Risks, and Management Commentary

Outlook: The company anticipates filing the full agreement as an exhibit to its 2023 Form 10-K. Success depends on the FDA's decision on the New Drug Application (NDA) for reproxalap and AbbVie's decision to exercise the option.

Risks and Contingencies:

• Funding Risk: If the option is not exercised, Aldeyra must fund further development and commercialization independently, which may require raising additional capital.
• Commercialization Risk: If Aldeyra must commercialize alone, it faces challenges in building a sales force or contracting third parties, which could be expensive and delay launch.
• Collaboration Risk: Even if the option is exercised, the joint commercialization plan may not achieve desired outcomes.
• Forward-Looking Statements: The filing contains forward-looking statements regarding FDA approval timing and the likelihood of option exercise, which are subject to significant uncertainty.

Investor Verification Checklist

• Verify the status of the FDA NDA for reproxalap and the PDUFA target action date.
• Monitor whether AbbVie pays the $5 million Option Extension Fee by the December 15, 2023 deadline.
• Confirm if AbbVie delivers an Option Exercise Notice within the defined Exercise Period.
• Review Aldeyra's cash position in upcoming filings to assess ability to fund operations if the option is not exercised.
• Check for the filing of the full Option Agreement and Collaboration Agreement in the 2023 Form 10-K.